While most patients clinically diagnosed with Alzheimer's had evidence of cerebrospinal fluid (CSF) amyloid and tau pathology ...

Researchers at Cedars-Sinai have made an important discovery: some patients who are diagnosed with a serious brain disease ...

BrainStorm Cell Therapeutics Inc. , a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in the 4th Annual ALS Drug Development Summit, to take ...

A new fluid biomarker for Parkinson’s disease (PD) was developed, offering a high-accuracy biological classification, ...

Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting central nervous system (CNS) cancers, announced today the result ...

While most patients clinically diagnosed with Alzheimer's had evidence of cerebrospinal fluid (CSF) amyloid and tau pathology, those biomarkers also emerged in people with other dementias ...

The biotech’s Huntingtin-targeting molecule lowered blood levels of the protein and elicited functional improvements in ...

Researchers have identified a biomarker in spinal fluid that can detect Parkinson’s disease in its early stages with over 90% ...

ALBANY — Albany Medical Center is participating in a clinical trial of the first minimally invasive option to treat normal ...